Brief: Biophytis: Positive Post-HOC Analysis Of Phase 2-3 COVA Clinical Study

Biophytis SA

03/11/2022 07:07

Nov 3 (Reuters) - Biophytis SA  ALBPS.PA :
    * BIOPHYTIS REPORTS POSITIVE POST-HOC ANALYSIS OF THE PHASE
2-3
COVA CLINICAL STUDY STRONGLY SUPPORTING THERAPEUTIC POTENTIAL OF
SARCONEOS (BIO101) IN COVID-19
    * A REDUCTION IN RISK OF EARLY DEATH OR RESPIRATORY FAILURE
AT DAY
28 OF 45% IN INTENT-TO-TREAT (ITT) POPULATION AND 53% IN PER
PROTOCOL (PP) POPULATION
    * A REDUCTION IN RISK OF DEATH AT DAY 90 OF 43% IN ITT
POPULATION
AND 70% IN PP POPULATION
    * START OF REGULATORY DEVELOPMENT OF SARCONEOS (BIO101)
TARGETING
CONDITIONAL AND EMERGENCY USE MARKETING AUTHORISATIONS IN 2023

Source text for Eikon:  ID:nEQ52d6bfa 
Further company coverage:  ALBPS.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))